Table 4.
Characteristic | Univariable analysis | Multivariable analysis | ||
---|---|---|---|---|
HR (95% CI) | P‐value* | HR (95% CI) | P‐value* | |
Age ≥ 50 y | 0.97 (0.91‐1.03) | .332 | 1.07 (0.99‐1.15) | .068 |
Race | ||||
White | 1 (reference) | 1 (reference) | ||
Black | 1.28 (1.19‐1.37) | <.001 | 1.02 (0.94‐1.11) | .667 |
Other | 0.83 (0.73‐0.94) | .004 | 0.78 (0.68‐0.89) | <.001 |
Unknown | 0.15 (0.05‐0.47) | .001 | 0.11 (0.03‐0.38) | <.001 |
Marital status | ||||
Married | 1 (reference) | 1 (reference) | ||
Unmarried | 1.45 (1.36‐1.54) | <.001 | 1.12 (1.04‐1.20) | <.001 |
Unknown | 1.16 (1.01‐1.33) | .042 | 1.09 (0.95‐1.26) | .23 |
Tumor grade | ||||
I/II | 1 (reference) | 1 (reference) | ||
III/IV | 1.46 (1.34‐1.60) | <.001 | 1.19 (1.08‐1.32) | <.001 |
Unknown | 2.07 (1.75‐2.46) | <.001 | 1.02 (0.82‐1.27) | .864 |
T stage | ||||
T1 | 1 (reference) | 1 (reference) | ||
T2 | 2.78 (2.55‐3.02) | <.001 | 2.06 (1.88‐2.26) | <.001 |
T3 | 6.78 (6.12‐7.49) | <.001 | 3.27(2.91‐3.67) | <.001 |
T4 | 13.57 (12.27‐15.01) | <.001 | 3.76 (3.30‐4.29) | <.001 |
N stage | ||||
N0 | 1 (reference) | 1 (reference) | ||
N1 | 3.50 (3.26‐3.77) | <.001 | 2.28 (2.10‐2.48) | <.001 |
N2 | 5.62 (5.11‐6.18) | <.001 | 3.45 (3.09‐3.87) | <.001 |
N3 | 10.22 (9.31‐11.22) | <.001 | 4.01 (3.53‐4. 55) | <.001 |
Metastasis | 12.42 (11.48‐13.45) | <.001 | 3.61 (3.24‐4.01) | <.001 |
AC Histology | 0.35 (0.23‐0.55) | <.001 | 0.42 (0.27‐0.64) | <.001 |
Radiation therapy | 0.72 (0.68‐0.76) | <.001 | 0.85 (0.79‐0.92) | .001 |
Chemotherapy | 1.06 (0.98‐1.13) | .138 | 0.69 (0.63‐0.76) | <.001 |
Surgery | 0.17 (0.15‐0.18) | <.001 | 0.48 (0.43‐0.53) | <.001 |
Abbreviations: AC, apocrine carcinoma; CI, confidential interval; HR, hazard ratios; SHR, subdistribution hazard ratio.
P values from the competing risk regression model.